Clinical Trials Logo
  1. Home
  2. Postherpetic Neuralgia
  3. NCT00916942

Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN)

Postherpetic Neuralgia Clinical Trial

Official title:
An Open-Label Study Of The Use Of Topical Lidocaine (2.5%)/Prilocaine (2.5%) Cream As Pre-Treatment For NGX-4010 In Subjects With Postherpetic Neuralgia (PHN)

Clinical Trial Summary

This study is an open-label multi-center to evaluate the tolerability of treatment with NGX-4010 use with pre-patch topical application of a topical anesthetic cream. This is an open-label study. No hypothesis testing will be performed.

Eligible subjects will have PHN and a level of pain at an intensity level deemed appropriate for open-label treatment with NGX-4010, as judged by the Investigator. Painful areas of up to a maximum of 1000 cm2 will be pre-treated with lidocaine (2.5%)/prilocaine (2.5%) cream for 60 minutes followed by a single, 60-minute application of NGX-4010. Subjects may be on chronic pain medication regimens, but currently will not be using any topical pain medications on the affected areas, such as non-steroidal anti-inflammatory drugs, menthol, methyl salicylate, local anesthetics including Lidoderm® (lidocaine patch 5%), steroids or capsaicin.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00916942
Study type Interventional
Source NeurogesX
Contact
Status Completed
Phase Phase 2
Start date June 2009
Completion date July 2009
View Details
See also
  Status Clinical Trial Phase
Completed NCT04546334 - Erector Spinae Plane Block in Post-herpetic Neuralgia N/A
Completed NCT01688947 - Analgesic Efficacy and Safety of V116517 in Subjects With Moderate to Severe Chronic Pain Due to Postherpetic Neuralgia (PHN) Phase 2
Terminated NCT01744522 - Leech Therapy for Postherpetic Neuralgia N/A
Completed NCT00566904 - New Topical Treatment for Continued Pain After Shingles Phase 1
Completed NCT00478179 - Study of a Bupivacaine Patch (Eladur™) to Treat Post- Herpetic Neuralgia Phase 2
Completed NCT04099706 - Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT N/A
Terminated NCT01603394 - Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia Phase 4
Completed NCT01251211 - Botulinum Toxin in Peripheral Neuropathic Pain Phase 4
Completed NCT01228838 - Study of NGX-1998 for the Treatment of Postherpetic Neuralgia Phase 2
Completed NCT00612105 - Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN) Phase 2
Recruiting NCT04560361 - The Analgesic Effect of Electroacupuncture on Postherpetic Neuralgia N/A
Recruiting NCT05568186 - Correlation Between Thermal Patterns of Infrared Thermal Imaging and Clinical Phenotype in Patients With Postherpetic Neuralgia
Recruiting NCT04664530 - The Study on the Esketamine in the Treatment of Postherpetic Neuralgia Phase 4
Active, not recruiting NCT01508676 - Effects of Pennsaid on Clinical Neuropathic Pain N/A
Completed NCT00885586 - Acupuncture in Herpes Zoster Neuralgia (ACUZoster) Phase 4
Completed NCT00576108 - A 2 Week Study of Topical KD7040 in the Treatment of Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00981227 - Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Post-Herpetic Neuralgia Phase 2
Completed NCT00238511 - An Open-Label Follow-on Trial to Assess the Long-Term Safety and Efficacy of Oral SPM 927 in Subjects With Postherpetic Neuralgia (PHN) Phase 2
Completed NCT00007501 - Shingles Prevention Study Phase 3
Completed NCT04594226 - Electroacupuncture Therapy for Treating Postherpetic Neuralgia N/A